In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Rigolin, Gian Matteo;Cuneo, Antonio;
2023

Abstract

In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders (small lymphocytic lymphoma and high-count monoclonal B lymphocytosis) infected by SARS-CoV-2, including the development of post-COVID condition. Data from 1540 patients with CLL infected by SARS-CoV-2 from January 2020 to May 2022 were included in the analysis and assigned to four phases based on cases disposition and SARS-CoV-2 variants emergence. Post-COVID condition was defined according to the WHO criteria. Patients infected during the most recent phases of the pandemic, though carrying a higher comorbidity burden, were less often hospitalized, rarely needed intensive care unit admission, or died compared to patients infected during the initial phases. The 4-month overall survival (OS) improved through the phases, from 68% to 83%, p = .0015. Age, comorbidity, CLL-directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% patients had a reinfection, usually milder than the initial one, and 16.5% developed post-COVID condition. The latter was characterized by fatigue, dyspnea, lasting cough, and impaired concentration. Infection severity was the only risk factor for developing post-COVID. The median time to resolution of the post-COVID condition was 4.7 months. OS in patients with CLL improved during the different phases of the pandemic, likely due to the improvement of prophylactic and therapeutic measures against SARS-CoV-2 as well as the emergence of milder variants. However, mortality remained relevant and a significant number of patients developed post-COVID conditions, warranting further investigations.
2023
Visentin, Andrea; Chatzikonstantinou, Thomas; Scarfò, Lydia; Kapetanakis, Anargyros; Demosthenous, Christos; Karakatsoulis, Georgios; Minga, Eva; Chamou, Dimitra; Allsup, David; Cabrero, Alejandro Alonso; Andres, Martin; Antic, Darko; Baile, Mónica; Baliakas, Panagiotis; Besikli-Dimou, Sotiria; Bron, Dominique; Chatzileontiadou, Sofia; Cordoba, Raul; Correa, Juan-Gonzalo; Cuéllar-García, Carolina; De Paoli, Lorenzo; De Paolis, Maria Rosaria; Delgado, Julio; Dimou, Maria; Donaldson, David; Catherwood, Mark; Doubek, Michael; Efstathopoulou, Maria; Eichhorst, Barbara; Elashwah, Salma; Enrico, Alicia; Espinet, Blanca; Farina, Lucia; Ferrari, Angela; Foglietta, Myriam; Frederiksen, Henrik; Fürstenau, Moritz; García-Marco, José A; García-Serra, Rocío; Collado, Rosa; Gentile, Massimo; Gimeno, Eva; Glenthøj, Andreas; da Silva, Maria Gomes; Hakobyan, Yervand K; Herishanu, Yair; Hernández-Rivas, José Ángel; Herold, Tobias; Innocenti, Idanna; Itchaki, Gilad; Jaksic, Ozren; Janssens, Ann; Kalashnikova, Оlga B; Kalicińska, Elżbieta; Kater, Arnon P; Kersting, Sabina; Labrador, Jorge; Lad, Deepesh; Laurenti, Luca; Levin, Mark-David; Lista, Enrico; Lopez-Garcia, Alberto; Malerba, Lara; Marasca, Roberto; Marchetti, Monia; Marquet, Juan; Mattsson, Mattias; Mauro, Francesca R; Morawska, Marta; Motta, Marina; Munir, Talha; Murru, Roberta; Niemann, Carsten U; Rodrigues, Raquel Nunes; Olivieri, Jacopo; Orsucci, Lorella; Papaioannou, Maria; Pavlovsky, Miguel Arturo; Piskunova, Inga; Popov, Viola Maria; Quaglia, Francesca Maria; Quaresmini, Giulia; Qvist, Kristian; Rigolin, Gian Matteo; Ruchlemer, Rosa; Šimkovič, Martin; Špaček, Martin; Sportoletti, Paolo; Stanca, Oana; Tadmor, Tamar; Capasso, Antonella; Del Poeta, Giovanni; Gutwein, Odit; Karlsson, Linda Katharina; Milosevic, Ivana; Mirás, Fatima; Reda, Gianluigi; Saghumyan, Gevorg; Shrestha, Amit; Te Raa, Doreen; Tonino, Sanne H; Van Der Spek, Ellen; van Gelder, Michel; van Kampen, Roel; Wasik-Szczepanek, Ewa; Wróbel, Tomasz; Segundo, Lucrecia Yáñez San; Yassin, Mohamed; Pocali, Barbara; Vandenberghe, Elisabeth; Iyengar, Sunil; Varettoni, Marzia; Vitale, Candida; Coscia, Marta; Rambaldi, Alessandro; Montserrat, Emili; Cuneo, Antonio; Stavroyianni, Niki; Trentin, Livio; Stamatopoulos, Kostas; Ghia, Paolo
File in questo prodotto:
File Dimensione Formato  
American J Hematol - 2023 - Visentin - The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic.pdf

accesso aperto

Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 3.56 MB
Formato Adobe PDF
3.56 MB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2530414
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact